Late-onset panhypopituitarism in a 72-year-old male patient treated with ipilimumab for metastatic melanoma: a case report
- 147 Downloads
KeywordsIpilimumab Enanthate Panhypopituitarism Lymphocytic Hypophysitis Testosterone Enanthate
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
We state that all procedures performed in this study were in accordance with the ethical standards of the research committee of our Institution and with the 1964 Helsinki Declaration and its later amendments.
A written informed consent was obtained by the patient mentioned in this manuscript.
- 2.Ryder M, Callahan M, Postow MA, Wolchok J, Fagin JA (2014) Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution. Endocr Relat Cancer 21(2):371–381. doi: 10.1530/ERC-13-0499 CrossRefPubMedPubMedCentralGoogle Scholar